Better understanding of the pathophysiology of RCC in recent years has shown the important role of hypoxia through HIF-1α pathways [10–13], which has led to successful application of antiangiogenic drugs targeting VEGF [14]. The gene discussed is VEGFA; the disease is renal cell adenocarcinoma.